MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
Tel: 301-354-3758
Website: https://macrogenics.com/capabilities/
Email: collaborate@macrogenics.com
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company developing and manufacturing a portfolio of innovative antibody-based products intended to extend and enhance the lives of people with cancer. We achieve this by leveraging the skills, passion, and scientific expertise of our employees and partners. Part of this mission includes providing our expertise in biopharmaceutical development and manufacturing to CDMO clients via our FDA-licensed commercial manufacturing facility. Our GMP suite utilizes single-use technology for maximum speed and flexibility and is outfitted for production of mammalian drug substance at the 500 L or 2000 L scale. In addition to manufacturing, we offer a fully customizable CDMO package with optional development services and analytical testing.
MacroGenics is committed to redefining CDMO relationships through efficient collaboration, client prioritization and transparency. Ensuring your values align with our company culture is as important to us as ensuring your process fits our facility.
If you are interested in learning more about our CDMO capabilities, come check us out in Rockville, Maryland! Reach out to schedule a meeting and tour of our facility to discuss your CDMO needs.
Stock Symbol: MGNX
Stock Exchange: NASDAQ
255 articles about MacroGenics, Inc.
-
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
3/7/2024
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
-
MacroGenics to Participate in Upcoming March 2024 Investor Conferences
3/1/2024
MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in March 2024.
-
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
2/27/2024
MacroGenics, Inc. (Nasdaq: MGNX) today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024.
-
MacroGenics to Participate in Upcoming Investor Conference - February 02, 2024
2/2/2024
MacroGenics, Inc. announced that the Company's management will participate in the following upcoming investor conference.
-
MacroGenics to Participate in Upcoming Investor Conference - Jan 08, 2024
1/8/2024
MacroGenics, Inc. announced that the Company's management will participate in the following upcoming investor conference:
-
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
11/6/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.
-
MacroGenics to Participate in Upcoming November 2023 Investor Conferences
11/2/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following upcoming investor conferences.
-
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
10/31/2023
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023.
-
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
9/5/2023
MacroGenics, Inc. announced that its partner, Gilead Sciences, Inc., nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies.
-
MacroGenics to Participate in Upcoming September 2023 Investor Conferences
8/31/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following upcoming investor conferences.
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
8/9/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2023.
-
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
7/31/2023
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2023 after the market closes on Wednesday, August 9, 2023.
-
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
5/9/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2023.
-
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
5/4/2023
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.
-
MacroGenics to Participate in Upcoming April 2023 Investor Conferences
4/24/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following upcoming investor conferences.
-
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
3/22/2023
MacroGenics, Inc. (NASDAQ: MGNX) today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte.
-
MacroGenics Provides Corporate Update and 2022 Financial Results
3/15/2023
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2022.
-
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
3/8/2023
MacroGenics, Inc. announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million.
-
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
3/7/2023
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.
-
MacroGenics to Participate in Upcoming March 2023 Investor Conferences
3/2/2023
MacroGenics, Inc. announced that the Company's management will participate in the following investor conferences in March 2023: